Clinical trials: Sphenopalatine Ganglion Block
Chronic Migraine
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
Migraine imposes a substantial burden on patients in terms of diminished daily functioning, quality of life, and financial loss.
- Trial name
- Tx360 (NCT01709708)
- Testing
- Marcaine, Saline
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tian Medical Inc.
Headache
SPG Blocks for Headaches
This will be a single-center, open-label clinical trial comparing sphenopalatine ganglion blocks to standard intravenous therapy for patients who come to the emergency department for a headache.
- Trial name
- NCT04255420
- Testing
- SPG Block, Standard IV Treatment
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Kendall Healthcare Group, Ltd.
Headache, Migraine
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
This is a double blind placebo-controlled study which will evaluate the efficacy of bupivacaine compared to saline, delivered by the Tx360® device to the sphenopalatine ganglion (SPG), to treat chronic migraine headache.
- Trial name
- NCT03337620
- Testing
- Tx360
- Where
- 11 sites in United States
- Volunteers
- 174 people
- Sponsor
- Tian Medical Inc.